1
Food and Drug AdministrationCardiovascular and Renal Drugs
Advisory Committee
Levitra® Tablets (NDA 21-400)(vardenafil HCl)May 29, 2003
2
Introduction
Mary E. Taylor, MPH Bayer Pharmaceuticals Corporation Vice President, Regulatory Affairs
North America
3
AgendaIntroduction Mary Taylor, MPH
Vice PresidentRegulatory Affairs North AmericaBayer Pharmaceuticals Corporation
Assessment of the QT/QTcEffect of Vardenafil
Thomas Segerson, MDVice PresidentMedical and Scientific AffairsBayer Canada
QT/QTc Study Design,Heart Rate Correction &Risk of Cardiac Arrhythmia
Joel Morganroth, MDClinical Professor of MedicineUniversity of PennsylvaniaChief ScientisteResearchTechnology
4
ConsultantsJoel Morganroth, MD Clinical Professor of Medicine
University of PennsylvaniaChief ScientisteResearchTechnology
John Camm, MD Professor of Clinical CardiologySt. George's HospitalLondon
Gerald Faich, MD Pharmaceutical Safety Assessments, Inc.
Gary Koch, PhD Professor of BiostatisticsUniversity of North Carolina
Udho Thadani, MD Professor of Medicine, Cardiovascular SectionUniversity of Oklahoma
5
Levitra® Tablets(vardenafil HCl)
Proposed Indication: Levitra is indicated for the treatment of erectile dysfunction defined as the consistent or recurrent inability to attain and/or maintain a penile erection sufficient for sexual performance.
Dosage and Administration: 5, 10, 20 mg (starting dose 10 mg) may be titrated up or down
6
Regulatory History
NDA submitted September 2001
Approvable letter received July 23, 2002
Application is currently under review
Approved in 34 countries including the UK, Germany, and 13 other EU countries; Australia; New Zealand; and several Latin American countries
7
Timeline
1998 1999 2000 2001 2002 2003
12/97 EUGuidance
3/01 HealthCanada
11/02 FDA Concept Paper
2/02 ICH SafetyPharmacology
QT Interval RegulatoryActivities
Phase III
3/03 EuropeanLaunch
7/02 Approvable Action
5/03 Advisory Committee
9/01 Levitra NDASubmitted
Vardenafil Development
8
Cardiovascular & Renal Drugs Advisory Committee Topics
Clinical trial design for the assessment of QT/QTc prolongation
Approaches to the correction of the QT interval for drugs that affect heart rate
The risk of cardiac arrhythmia associated with different degrees of QT/QTc prolongation
9
Assessment of the QT/QTc Effect of
VardenafilThomas P. Segerson, MD
Vice PresidentMedical and Scientific Affairs
Bayer Canada
10
Agenda
Background information on vardenafil Pharmacology and mechanism of action Efficacy and adverse event profile Human pharmacokinetics
Vardenafil data relevant to QT/QTc assessment Preclinical effects Clinical pharmacology Phase III clinical studies
Study to rigorously evaluate the QT/QTc effect of vardenafil
11
Vardenafil: Pharmacology and Mechanism of Action
Vardenafil is a potent PDE5 (phosphodiesterase type 5) inhibitor (IC50 ~1 nM).
Vardenafil is highly specific for the type 5 PDE isoenzyme, inhibition of which leads to cyclic guanosine monophosphate (cGMP) accumulation and corpus cavernosum smooth muscle relaxation.
Transient effects of vardenafil on BP and HR are consistent with the distribution of PDEs in vascular tissue.
12
Vardenafil Efficacy Data in General and ‘Resistant to Treatment’ ED Populations
†International Index of Erectile Function
Me
an
EF
Do
ma
in† S
core
Cha
nge NA Pivotal Study 100249
Treatment Group
8.27.4
5.2
1.8
0
2
4
6
8
Placebo 5 mg 10 mg 20 mg
*
**
7.8
5.9
1.4
0
2
4
6
8
Placebo 10 mg 20 mg
*
*
*p <0.01 vs placebo
Diabetes Study 100250
13
Frequent Adverse Events* in Placebo-Controlled Phase III Trials
Percentage of Patients with ReportedEvent
Adverse Event PlaceboN = 1199
(%)
VardenafilN = 2203
(%)Any Event 33 53Headache 4 15Flushing 1 11Rhinitis 3 9Dyspepsia 1 4Accidental Injury 2 3Sinusitis 1 3Flu Syndrome 2 3Dizziness 1 2Increased CK 1 2Nausea 1 2
* 2% and more frequent with vardenafil than placebo
14
Time (hrs)
0 6 12 18 24
vard
en
afil
co
nce
ntr
atio
n (
ng
/ml)
0
5
10
15
20
Concentration at 24h1 - 2% Cmax
Pharmacokinetic Profile of Vardenafil after Single 20 mg Oral Dose in Men
Elimination:• Hepatic 91-95%• Renal 2-6%
Study 10118, n = 24
mea
n
15
Time (h)
0 4 8 12 16
Co
nce
ntr
atio
n n
g/m
l
0.1
1
10
100
Human Pharmacokinetics of Vardenafil and Metabolites
Peak concentration of metabolites 50% of vardenafil
M1-glucuronide
M1M4M5
14C study (10079), n=4
M1, M4 and M5 are deethylation/ demethylation products of vardenafilmetabolism
vardenafil
16
Pharmacokinetic Interaction of Vardenafil with Ritonavir
vardenafil 5mg
vardenafil 5mg &
ritonavir*
vardenafil
80mg
*interaction assessed on 10th day of ritonavir 600 mg BID dosing
Cm
ax (
ng/
ml)
Study 100535
17
In vitro evaluation showed an IC50 of 30 M for vardenafil, and 47 M for sildenafil for inhibition of hERG potassium channel, at least 1000-fold above free concentration after maximum clinical dose*
No QTc prolongation found in vivo in Beagle dogs: preclinical model as per guideline pattern of vardenafil metabolites similar to human safety pharmacology studies up to 10 mg/kg in anesthetized and
conscious Beagle dogs Tested concentrations 100-fold greater than the human exposure
(Cmax) to vardenafil after 20 mg and 10-fold greater than exposure to M1 and M4 metabolites
Preclinical QT Data
*Sildenafil 100 mg (NDA #20-885 SBA), Vardenafil 20 mg (Study 100196)
18
ECG Evaluation in Vardenafil NDA Clinical Pharmacology Program
Paired ECGs were obtained in 6 placebo-controlled studies as part of standard safety assessment of doses up to 80 mg
These studies were not designed specifically to detect a QT/QTc effect
Equivocal changes on QT/QTc were observed with no obvious dose relationship
19
Placebon=1199 (%)
Vardenafiln=2203 (%)
Adverse Event
Syncope 1 (<0.1) 2 (<0.1)
Dizziness 11 (0.9) 48 (2.2)
Palpitations 3 (0.3) 11 (0.5)
Seizures(convulsions)
0 (0) 1 (<0.1)
Incidence of Clinical Adverse Events Which May be a Potential Signal for Ventricular Arrhythmia in
Placebo-Controlled Phase III Studies
No events of TdP reported in clinical trials with vardenafil
20
All Cause Mortality in Clinical Trials• Nine deaths in patients before receiving study treatment
• Seven deaths in completed phase II/III studies*
1 of 1351 on placebo (0.07%)
1 of 164 on sildenafil (0.61%)
4 of 4814 on vardenafil (0.08%)
1 randomized to vardenafil but did not take drug
• No deaths on vardenafil were assessed as being related to vardenafil treatment.
*As of January 2003
21
Study 10929/011: Effect of Vardenafil on QT/QTc Interval Goal of study to define effects of vardenafil on QT/QTc interval:
At therapeutic doses
At supratherapeutic doses
At plasma concentrations following maximal potential interaction with CYP 3A4 inhibitors
Study design discussed and agreed with FDA
Performed by Clinical Pharmacology and Statistics, GSK Pharmaceuticals
22
Study 10929/011: Objectives and Design
Primary Objective: Exclude a greater than 10 msec change from baseline 1-hour post-dose on QTcF interval compared to placebo after vardenafil 80 mg
Secondary Objectives:• change from baseline of QT/QTc versus placebo at Tmax
• maximal change from baseline of QT/QTc versus placebo over 4 hr
Design: Six-way crossover, single-dose, placebo-controlled study. Doses evaluated, period of evaluation, positive control, statistical analysis all agreed with FDA.
Treatments: •Vardenafil 80 mg•Vardenafil 10 mg•Moxifloxacin 400 mg
•Sildenafil 400 mg •Sildenafil 50 mg•Placebo
23
Study 10929/011 Methodology
59 healthy subjects, age range 45-60 years
QT interval determined by a validated central laboratory
blinded to treatment; manual digital measurements of 3
beat average in Lead II
End of T-wave identified by return to baseline (or, if not
possible, tangent method)
Subjects were non-ambulatory, supine, fasting
24
Study 10929/011 Procedures
Time (h)
Dose
Baseline
Study 10929/011
6 ECGs at each timepoint one minute apart
25
QTraw , HR, and QTcF Mean Change from Baseline (SE) 1 hour
after Placebo
Treatment QTraw
(msec)
HR
(bpm)
QTcF
(msec)
Placebo 6 (1.0) -3 (0.5) 0 (0.7)
Study 10929/011; n=58
26
Placebo-Subtracted Mean Change from Baseline (90% CI) for QTraw, HR and
QTcF at 1 Hour
Treatment effect (90% CI)
Treatment QTraw(msec)
HR(bpm)
QTcF(msec)
80 mg vardenafil -2 (-4, 0) 6 (5, 7) 10 (8, 11)
10 mg vardenafil -2 (-4, 0) 5 (4, 6) 8 (6, 9)
400 mg sildenafil -1 (-3, 1) 5 (4, 6) 9 (8, 11)
50 mg sildenafil -2 (-4, 0) 4 (3, 5) 6 (5, 8)
400 mg moxifloxacin 3 ( 1, 5) 2 (1, 3) 8 (6, 9)
Study 10929/011; n=58
27
Individually Corrected QT: QTci
Alternative to fixed approach to heart rate correction (Fridericia, Bazett)
Correction based on each subject’s RR-QT relationship Based on placebo and baseline data (n = 138 per subject)
Two approaches Linear relationship, QTci = QT + slope(1-RR) Non-linear relationship, QTciX = QT/(RR)x
Same analyses performed as for QTcF
Study 10929/011
28
Placebo-Subtracted Mean Change from Baseline for QTcF and QTci* at 1 hour
(Point Estimates of Treatment Effect and 90% CI)
vardenafil 80 mg
10 mg
sildenafil 400 mg
50 mg
moxifloxacin 400 mg
QTcF (msec) QTci (msec)Study 10929/011; n=58
* linear relationship
29
Placebo-Subtracted Mean Change from Baseline for QTcF and QTci* (msec) at 1
Hour Post-Dose
Treatment effect (90% CI)
Treatment QTcF(msec)
QTci(msec)
80 mg vardenafil 10 (8, 11) 6 (4, 7)
10 mg vardenafil 8 (6, 9) 4 (3, 6)
400 mg sildenafil 9 (8, 11) 5 (4, 7)
50 mg sildenafil 6 (5, 8) 4 (2, 5)
400 mg moxifloxacin 8 (6, 9) 7 (5, 8)
Study 10929/011; n=58*linear relationship
30
Placebo-Subtracted Mean Change from Baseline for QTcF at 1 Hour, Tmax, and
Maximum QTcF
Treatment Effect (90%CI)
Treatment 1 hour Tmax Maximum QTcF
80 mg vardenafil 10 (8, 11) 9 (8, 11) 9 (7, 10)
10 mg vardenafil 8 (6, 9) 7 (5, 9) 6 (5, 7)
400 mg sildenafil 9 (8, 11) 6 (4, 7) 8 (7, 9)
50 mg sildenafil 6 (5, 8) 6 (5, 8) 5 (4, 6)
400 mg moxifloxacin 8 (6, 9) 8 (7, 10) 9 (7, 10)
Study 10929/011; n=58
31
No QTraw value 500 msec
No QTcF value 450 msec
No change in QTcF 60 msec
Only one subject (sildenafil 400 mg) with mean QTcF change 30 msec at any time point (average of 6 ECGs)
QT/QTc Outlier Analysis
Study 10929/011; n=59
32
Observed & Population Predicted QTcF versus Vardenafil Plasma Concentration
33
Summary
In clinical trials, vardenafil has been shown to be safe and effective for the treatment of erectile dysfunction in men.
Preclinical studies with vardenafil do not predict QT/QTc prolongation or arrhythmia at clinically relevant concentrations.
In the clinical development program, there was no evidence of TdP.
34
Summary (continued)
A QT/QTc study of vardenafil 10 and 80 mg conducted in accordance with current regulatory guidance demonstrated a 4-10 msec mean maximum QTc prolongation.
Vardenafil shortened uncorrected QT duration compared to placebo, whereas moxifloxacin lengthened it.
Vardenafil concentrations achieved cover the range following strong metabolic inhibition.
The relationship between corrected QT values and vardenafil doses/concentrations is very shallow (2 msec increment with 8-fold increase in dose).
Vardenafil effect on the QT/QTc interval is similar to that of sildenafil, an approved drug in the same class.
35
QT/QTc Study Design, Heart Rate Correction & Risk of Cardiac
Arrhythmia
Joel Morganroth, MDClinical Professor of Medicine
University of PennsylvaniaChief Scientist
eResearchTechnology
36
Agenda
QT/QTc study design issues
QT correction factor analysis
Clinical relevance of 5 to 10 msec QTc effect
37
FDA-Health Canada Preliminary Concept Paper: November 2002
The document recommends:
Robust and valid determination of cardiac risk (QT/QTc duration) using a validated ECG laboratory with specific design recommendations
All bioactive compounds should undergo a “definitive” Phase I QT/QTc assessment
38
What are the design issues in a “definitive” Phase I QT/QTc trial that should be considered in light of the marked spontaneous variability in
QTc duration?
39
Managing Sources of QTc Variability Sample size: usually need >30 per arm to detect small QTc effect with
adequate power [used 59]
Frequency of baseline and on-therapy ECGs to cover maximum concentration of parent and metabolites; diurnal variation [n=18 at baseline and 30 on each therapy at the same time of day]
ECG measurement precision: digital process with manual method in a validated core ECG laboratory [done]
Population: male and female volunteers [all men due to therapeutic use; age 45-60 yrs]
Conditions of the ECG recording (e.g., subjects resting, supine, ECG taken before blood sampling) [done]
40
Other Aspects of QT/QTc Trial Design
Dose ranging (at least 2 doses, one of which is an appropriate multiple of the recommended dose) - no need to study metabolic inhibitors if supratherapeutic dose meets theoretical maximum exposure
[1x and 8x recommended starting clinical dose] Control groups: placebo (interpret spontaneous variability) and
positive (assay sensitivity) [both done]
Correction of QT (Fridericia, population, individual, Bazett) [Fridericia and individual reported]
Statistical plan: placebo-corrected, central tendency and outlier analyses
[all done]
41
Drug-Specific Factors to Consider in the Design of a QT/QTc Study
Pharmacokineticsto ensure observation period covers Cmax of parent and
metabolites [4-hour sampling appropriate]to ensure no carryover effects in a crossover trial [PK of parent
and metabolites appropriate for crossover]
Therapeutic use single- vs multiple-dose study [single-dose trial appropriate]
Heart rate effects of drugconsider special procedures for heart rate correction when drug
increases heart rate [QTci analysis done]
42
“The traditionally used Bazett’s formula for correction ofthe measured QT interval for variations in heart rates(QTc = QT/RR0.50) has limitations for drugs that significantly increase the heart rate.”
“Although none of the 30 or so formulae available is entirely satisfactory, the Fridericia correction (QTc =QT/RR0.33), or preferably a study-specific derived formula (QTc =QT/RRx), may be more appropriate.”
Shah Fundamental & Clinical Pharmacology (2002) 16: 147–156.
What Correction Formula Should be Used to Derive QTc from Heart Rate and QT?
43
Which Correction Formula Should be Used to Derive QTc from Heart Rate and QT?
FDA-Health Canada concept paper, November 2002:
“...heart rate corrections using individual patient data have been proposed, applying regression analysis techniques to obtain individual pretherapy QT/RR interval data over a range of heart rates, then looking for a change in regression line with treatment.”
Practical limitations of this approach: heart rate range at baseline Need for 50-100 ECGs off therapy [combine baselines and placebo
in crossover trials]
44
Placebo-Subtracted Mean Change from Baseline for QTcF and QTci* at 1 hour
(Point Estimates of Treatment Effect and 90% CI)
vardenafil 80 mg
10 mg
sildenafil 400 mg
50 mg
moxifloxacin 400 mg
QTcF (msec) QTci (msec)Study 10929/011; n=58
* linear relationship
45
Placebo-Subtracted Mean Change from Baseline for QTc (msec) at 1 hr Post-Dose
Treatment Effect (90% CI)
Treatment QTcF QTci(linear)
QTci(nonlinear)
10 mg vardenafil 8 (6,9) 4 (3,6) 4 (3,6)
80 mg vardenafil 10 (8,11) 6 (4,7) 6 (5,8)
50 mg sildenafil 6 (5,8) 4 (2,5) 4 (2,5)
400 mg sildenafil 9 (8,11) 5 (4,7) 6 (4,7)
400 mg moxifloxacin 8 (6,9) 7 (5,8) 7 (5,8)
Study 10929/011;n=58
46
Population QTc vs HR: Bazett’s and Fredericia
QTcB
HR (bpm)
QTc
(m
sec)
40 60 80 100
350
400
450
QTcF
HR (bpm)Q
Tc (
mse
c)
40 60 80 100
350
400
450
Note: data plotted is baseline and placebo data only
47
Population QTc vs HR: Fredericia and Individual
Note: data plotted is baseline and placebo data only
QTcF
HR (bpm)
QTc
(m
sec)
40 60 80 100
350
400
450
QTciX
HR (bpm)
QTc
(m
sec)
40 60 80 100
350
400
450
48
Individual QTc vs HR relationships: Fridericia and Individual
QTcF
HR (bpm)
QTc
(m
sec)
40 60 80 100
360
380
400
420
QTciX
HR (bpm)Q
Tc (
mse
c)40 60 80 100
360
380
400
420
Note: Data represents fitted linear relationship for baseline and placebo data only
49
Individual QTci.2 vs HR Relationships
QTci
HR (bpm)
QTc (
msec)
40 60 80 100
360
380
400
420
QTci.2
HR (bpm)Q
Tc (
msec)
40 60 80 100
360
380
400
420
N = 59 Patients
Analysis conducted by FDA biostatistician
Individual correction (linear) based on baseline data only (n = 108 vs. 138 ECGs)
QTci.2/HR relationship: applied to both baseline and placebo data
Thus, “The more data used the better the QTci”
50
QTc Statistical Reporting Issues
Central tendency Mean change Mean maximal change
Categorical analysis looking for outliers % of patients (not observations) with:
a change from baseline of 30-60 msec (sensitive) and 60 msec (specific)
new value 500 msec new abnormal T-U waves
51
Number of ECGs with Changes from Baseline 30-60 msec in QTci
Regimen
Frequency (%) V10 V80 S50 S400 M P Total
QTci 30<60 2
(0.11)
4
(0.23)
1
(0.06)
4
(0.23)
18
(1.03)
1
(0.06)
30
(0.29)
Total 1740 1740 1740 1740 1740 1740 10440
52
Results of the Vardenafil QT/QTc Study
I consider the trial to be valid and the results reliable Placebo and the positive control, moxifloxacin,
behaved as anticipated in the study placebo = 0 msec; moxifloxacin = 8 msec
Vardenafil 10 and 80 mg produced 4 -10 msec change from baseline at 1 hr and at Tmax, using QTcF or QTci
Shallow dose response (8x starting dose)
53
Results of the Vardenafil QT/QTc Study(cont’d)
QT/QTc effects comparable to sildenafil
Vardenafil and sildenafil shortened uncorrected QT duration compared to placebo, whereas moxifloxacin lengthened it
Outliers None 60 msec No new > 500 msec No subjects on vardenafil and only 1 subject in sildenafil
group with > 30 msec change
54
Clinical Relevance of a Drug-Induced QT/QTc Effect: Risk Assessment
Experience with other compounds terfenadine, cisapride, ziprasadone . . . moxifloxacin
Post-marketing surveillance data moxifloxacin PMS data sildenafil PMS data (similar QT/QTc effect and same
therapeutic class)
Regulatory opinions FDA-Health Canada concept paper Medicines Control Agency (EMEA/CPMP)
55
Terfenadine Mean change in QTc across the 12-hour dosing intervala:
6 msec
Mean change in QTc at Tmax (mean maximum change)a:
18 msec
Mean change in the presence of a metabolic inhibitor (ketoconazole)b:
up to 82 msec
a Morganroth, et al., Am J Cardiol 72:26B-32B, 1993b Honig, et al., JAMA 269: 1513-1518, 1993
56
Moxifloxacin
hERG channel blockade at concentrations approaching clinical concentrations
Mean maximum QTc effect = 6-10 msec increase (400 mg PO) and a doubling of the effect with 800 mg PO
Minimal effect on heart rate
Prolongs both QT and QTc
57
Two post-marketing observational studies (n ~ 55,000)
No cases of Torsades de Pointes
No signal of cardiac arrhythmia or a QT interval prolongation-related cardiac rhythm disorder
Moxifloxacin Cardiac Safety: Post-Marketing Surveillance
58
Moxifloxacin Spontaneous Reports of Torsades de Pointes as of May 7, 2003
• Moxifloxacin (19 million patients; 8-day average prescription; 416,000 patient-years): N=12 TdP• Oral: 4 US, 4 Europe• IV: 3 US and 1 Europe
• All 12 cases showed marked confounders except 2 oral (1 with no clinical data)
• Rate of TdP on oral moxifloxacin in US• 4 per 7.7 million patients• Comparable to other antibiotics (Brinker FDA)
59
Sildenafil FDA AERS Data
Torsades de Pointes:
No cases reporteda from launch to December 15, 2002 (data lock)
Usage:b
38.7 million sildenafil prescriptions written worldwide from April 1998 to December 2002
aSpontaneous reports from FDA Adverse Event Reporting System databasebUsage data from IMS
60
What Does a 5 to 10 msec QTc Increase Mean?
FDA concept paper notes importance of magnitude of mean maximal QT/QTc effect:
< 5 msec no TdP5 - 10 msec no clear risk10 - 20 msec some concern> 20 msec substantially increased
likelihood of being
proarrhythmic
QT is a surrogate. There is good evidence (dofetilide, sotalol, terfenadine) that the size of the effect relates to risk of TdP, but there could be other properties that mitigate or enhance risk.
- Robert Temple, January 2003, Shady Grove Meeting
61
Additional Considerations in the Assessment of the Clinical Relevance of
Vardenafil’s QTc Effect
The drug is indicated for use in males (risk of drug-induced TdP lower in males)
Single dose, used intermittently
Shallow dose response for QTc effects
Vardenafil tends to increase heart rate
62
Conclusions: About Vardenafil
In a definitive QT/QTc trial, vardenafil and sildenafil showed comparable maximum QTci effects on cardiac repolarization of about 5 msec over an 8x dose range
This magnitude is generally considered by regulatory authorities as not associated with TdP
No clinically significant outliers with vardenafil
Post-marketing surveillance data for sildenafil provides no reports of TdP
Thus, the QTc effect of vardenafil should not pose a cardiac safety concern
63